NCT05576103 Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
| NCT ID | NCT05576103 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jona Hattangadi-Gluth |
| Condition | Primary Brain Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2015-01 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2015-01 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Patients 18 years or older 2. Karnofsky performance status (KPS) ≥70 3. Life expectancy of ≥1 year 4. Primary brain tumor patients who will receive fractionated partial brain RT 5. Able to complete neurocognitive assessments Exclusion Criteria: 1. Inability to undergo MRI with contrast 2. Prior brain RT
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05576103 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Primary Brain Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05576103 currently recruiting?
Yes, NCT05576103 is actively recruiting participants. Contact the research team at s4medina@health.ucsd.edu for enrollment information.
Where is the NCT05576103 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT05576103 clinical trial?
NCT05576103 is sponsored by Jona Hattangadi-Gluth. The trial plans to enroll 300 participants.